Boehringer Ingelheim has received fast track designation from the FDA for the development of Jardiance (empagliflozin) to prevent hospitalization for heart failure and reduce the risk of mortality in patients who experienced a heart attack.
Jardiance is a drug used for lowering blood sugar in adults with type 2 diabetes and reducing the risk of cardiovascular death in adults with type 2 diabetes and known cardiovascular disease.
more